Other languages Argenica Therapeutics Limited

Equities

AGN

AU0000150328

Delayed Australian S.E. Other stock markets 22:04:33 2024-05-01 EDT			5-day change	1st Jan Change
0.58 ^AUD	-0.85%		+6.42%	+13.73%

04-16	Euroz Hartleys Adjusts Argenica Therapeutics’ Price Target to AU$1.40 From AU$1.50, Keeps at Speculative Buy	MT
04-12	Argenica Therapeutics Raises AU$12 Million via Placement	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Argenica Therapeutics Doses First Patient in Phase Two Stroke Trial; Shares Rally 14%	03-27
FDA Grants Argenica Rare Pediatric Disease Designation for Hypoxic Ischaemic Encephalopathy Treatment; Shares Up 16%	03-24
Argenica Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-27
Argenica Therapeutics Concludes Manufacturing, Release Testing for Stroke Drug; Shares Rise 3%	02-11
Argenica Therapeutics On Track for First Patient Dosing in Phase 2 ARG-007 Trial in Q1 2024	12-13
Argenica Therapeutics Appoints Nonexecutive Chair	11-29
Argenica Therapeutics Limited Announces Changes to its Board, Effective 1 December 2023	11-29
Argenica Therapeutics Secures US FDA Orphan Drug Designation for Neurological Medication	11-15
Argenica Therapeutics Secures AU$2 Million R&D Tax Rebate for Fiscal Year 2023	11-12
Argenica Therapeutics Limited Announces the Resignation of Dr. Samantha South as Executive Director Effective 30 November 2023	23-10-26
Argenica Therapeutics' Drug Candidate Reduces Brain Injury in Hypoxic-Ischemic Encephalopathy Preclinical Model	23-10-18
Argenica Therapeutics Secures Ethics Approval for Phase 2 Stroke Trial	23-09-12
Argenica Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-22
Preclinical Data Shows Argenica Therapeutics' ARG-007 Able to Mitigate Neurodegenerative Disorders	23-08-02
Argenica Therapeutics Files Ethics Application for Phase Two Stroke Trial	23-07-19
Argenica Therapeutics Validates Efficacy of Neuroprotective Drug in Preclinical Trial	23-06-23
Argenica Therapeutics Raises AU$4 Million for Phase Two Trial	23-06-01
Argenica Therapeutics Confirms Effectivity of Neuroprotective Medication in Preclinical Study; Shares Fall 5%	23-04-20
Argenica Therapeutics Validates Safety Profile of Neuroprotective Drug	23-03-06
Argenica Therapeutics Limited Releases Safety Data for its Phase 1 Clinical Trial of ARG-007 in Healthy Human Volunteers	23-03-05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Argenica Therapeutics Limited

Equities

AGN

AU0000150328

Other languages

Filters